Human Papillomavirus (HPV) Vaccine Global Market Report 2025

Description

The Human Papillomavirus (HPV) Vaccine is a preventive vaccine designed to protect against specific strains of human papillomavirus, reducing the risk of infection. These vaccines play a crucial role in preventing most occurrences of cervical, vaginal, and vulvar cancers.

The primary types of Human Papillomavirus (HPV) vaccines are tetravalent, nonavalent, and bivalent. Tetravalent vaccines activate the body's defenses against four distinct antigens, providing an immunological response against four different viruses or microbes. These vaccines target disease indications such as cervical cancer, anal cancer, vulvar and vaginal cancer, penile cancer, oropharyngeal cancer, and others. Distribution channels include hospitals, retail pharmacies, government suppliers, and others. The industry verticals involved encompass public and private alliances, government entities, physicians, and others.

The human papillomavirus (HPV) vaccine market research report is one of a series of new reports from The Business Research Company that provides human papillomavirus (HPV) vaccine market statistics, including human papillomavirus (HPV) vaccine industry global market size, regional shares, competitors with a human papillomavirus (HPV) vaccine market share, detailed human papillomavirus (HPV) vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) vaccine industry. This human papillomavirus (HPV) vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human papillomavirus (HPV) vaccine market size has grown rapidly in recent years. It will grow from $5.8 billion in 2024 to $6.63 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to initial vaccine development, medical guidelines and recommendations, government-sponsored vaccination campaigns, educational initiatives on HPV risks, improvement in vaccine accessibility

The human papillomavirus (HPV) vaccine market size is expected to see rapid growth in the next few years. It will grow to $10.89 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to health equity and vaccine equity efforts, inclusion in travel health recommendations, targeted vaccination strategies, pharmaceutical industry investments, telemedicine and remote vaccination. Major trends in the forecast period include innovation in adjuvant technology, role of HPV vaccination in lgbtq+ health, focus on immunocompromised populations, integration with cancer screening programs, community-based education programs.

The human papillomavirus (HPV) vaccine market is poised for growth, driven by the increased prevalence of HPV-related diseases. These viral infections often manifest as warts on the skin or mucous membranes, and the HPV vaccine specifically targets these subtypes, effectively mitigating the risk of infection and associated diseases. For instance, recent data from the National Cancer Institute indicates an anticipated diagnosis of approximately 13,960 cases of aggressive cervical cancer in American women, with an expected 4,310 fatalities in 2023. The alarming prevalence of HPV-related diseases, such as cervical cancer, underscores the imperative role of the HPV vaccine in curbing these health risks.

Increasing global immunization coverage is poised to drive growth in the human papillomavirus (HPV) vaccine market. Immunization coverage denotes the percentage of a population that has received specific vaccines or a recommended set of vaccines within a defined timeframe. The expansion of immunization coverage fuels heightened demand for HPV vaccines, which provide protection against virus strains incorporated into routine vaccination programs, effectively addressing multiple disease threats with a single shot. For example, as of July 2023, data from the World Health Organization (WHO), an international public health organization based in Switzerland, revealed positive trends. In 2022, the number of zero-dose children, indicating those who did not receive any vaccinations, decreased from 18.1 million in 2021 to 14.3 million. Additionally, global coverage for the initial dose of the HPV vaccine in girls witnessed an increase from 16% in 2021 to 21% in 2022. These developments underscore the positive impact of rising global immunization coverage on the growth trajectory of the HPV vaccine market in the foreseeable future.

A key trend in the human papillomavirus (HPV) vaccine market is the focus on product innovation, with companies adopting new technologies to maintain their market standing. For Instance, In January 2023, the Serum Institute of India introduced CERVAVAC, the first quadrivalent HPV vaccine developed entirely by Indian scientists. This innovative vaccine, aimed at immunizing girls aged 9 to 14 against cervical cancer, signifies a noteworthy advancement in the field and addresses the need for affordable and cost-effective solutions.

Major companies in the human papillomavirus (HPV) vaccine market are prioritizing innovative approaches, such as awareness campaigns aimed at educating communities about the benefits of vaccination. These campaigns are strategic initiatives designed to inform a specific audience or the general public about a particular issue, cause, product, or service. For example, in January 2023, the Family Planning Association of India, a charity based in India, launched a vaccine drive against cervical cancer, targeting girls aged 9 to 14 years. This nationwide HPV vaccination initiative seeks to protect girls and women from cervical cancer using a quadrivalent vaccine that targets key strains of the virus. The goal is to vaccinate approximately 50 million girls while raising awareness and improving access in both urban and rural areas.

In January 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, merged with the Serum Institute of India. This collaboration not only ensures a committed revenue stream and associated margins for Biocon Biologics Ltd. but also facilitates the development of antibodies targeting infectious diseases, including HPV. The Serum Institute of India, known for manufacturing qHPV vaccines and immuno-biologicals, reinforces the collective efforts to combat HPV-related health challenges.

Major companies operating in the human papillomavirus (HPV) vaccine market include Johnson & Johnson Co, Merck & Co Inc., Novartis AG, Sanofi SA, GlaxoSmithKline Plc, AstraZeneca Pharma Ltd., Astellas Pharma Inc., CSL Limited, UCB SA, Serum Institute of India Pvt Ltd., Beijing Wantai Biological Pharmacy Enterprise Co Ltd., Emergent BioSolutions Inc., Bharat Biotech International Ltd., Walvax Biotechnology Co Ltd., Bavarian Nordic AS, Biofarma Co, Vaccitech Plc, Inovio Pharmaceuticals Inc., R-Pharm LLC, PathoVax LLC

North America was the largest region in the human papillomavirus (HPV) vaccine market in 2024. The regions covered in the human papillomavirus (hpv) vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human papillomavirus (hpv) vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human papillomavirus (HPV) vaccine market consists of sales of gardasil 9, gardasil, and cervarix. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Papillomavirus (HPV) Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human papillomavirus (hpv) vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human papillomavirus (hpv) vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human papillomavirus (hpv) vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Tetravalent; Nonavalent; Bivalent
2) By Disease Indication: Cervical Cancer; Anal Cancer; Vulvar And Vaginal Cancer; Penile Cancer; Oropharyngeal Cancer; Other Indications
3) By Distribution Channel: Hospital And Retail Pharmacies; Government Suppliers; Other Channels
4) By Industry Vertical: Public And Private Alliance; Government Entities; Physicians; Other Industries
Subsegments:
1) By Tetravalent: HPV 4 (Cervarix); HPV 4 (Gardasil)
2) By Nonavalent: HPV 9 (Gardasil 9)
3) By Bivalent: HPV 2 (Cervarix)
Companies Mentioned: Johnson & Johnson Co; Merck & Co Inc.; Novartis AG; Sanofi SA; GlaxoSmithKline Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25014

1. Executive Summary

2. Human Papillomavirus (HPV) Vaccine Market Characteristics

3. Human Papillomavirus (HPV) Vaccine Market Trends And Strategies

4. Human Papillomavirus (HPV) Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Human Papillomavirus (HPV) Vaccine Growth Analysis And Strategic Analysis Framework

5.1. Global Human Papillomavirus (HPV) Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Papillomavirus (HPV) Vaccine Market Growth Rate Analysis
5.4. Global Human Papillomavirus (HPV) Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Papillomavirus (HPV) Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Papillomavirus (HPV) Vaccine Total Addressable Market (TAM)

6. Human Papillomavirus (HPV) Vaccine Market Segmentation

6.1. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tetravalent
Nonavalent
Bivalent
6.2. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cervical Cancer
Anal Cancer
Vulvar And Vaginal Cancer
Penile Cancer
Oropharyngeal Cancer
Other Indications
6.3. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital And Retail Pharmacies
Government Suppliers
Other Channels
6.4. Global Human Papillomavirus (HPV) Vaccine Market, Segmentation By Industry Vertical, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Public And Private Alliance
Government Entities
Physicians
Other Industries
6.5. Global Human Papillomavirus (HPV) Vaccine Market, Sub-Segmentation Of Tetravalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HPV 4 (Cervarix)
HPV 4 (Gardasil)
6.6. Global Human Papillomavirus (HPV) Vaccine Market, Sub-Segmentation Of Nonavalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HPV 9 (Gardasil 9)
6.7. Global Human Papillomavirus (HPV) Vaccine Market, Sub-Segmentation Of Bivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HPV 2 (Cervarix)

7. Human Papillomavirus (HPV) Vaccine Market Regional And Country Analysis

7.1. Global Human Papillomavirus (HPV) Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Papillomavirus (HPV) Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market

8.1. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Papillomavirus (HPV) Vaccine Market

9.1. China Human Papillomavirus (HPV) Vaccine Market Overview
9.2. China Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Papillomavirus (HPV) Vaccine Market

10.1. India Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Papillomavirus (HPV) Vaccine Market

11.1. Japan Human Papillomavirus (HPV) Vaccine Market Overview
11.2. Japan Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Papillomavirus (HPV) Vaccine Market

12.1. Australia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Papillomavirus (HPV) Vaccine Market

13.1. Indonesia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Papillomavirus (HPV) Vaccine Market

14.1. South Korea Human Papillomavirus (HPV) Vaccine Market Overview
14.2. South Korea Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Papillomavirus (HPV) Vaccine Market

15.1. Western Europe Human Papillomavirus (HPV) Vaccine Market Overview
15.2. Western Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Papillomavirus (HPV) Vaccine Market

16.1. UK Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Papillomavirus (HPV) Vaccine Market

17.1. Germany Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Papillomavirus (HPV) Vaccine Market

18.1. France Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Papillomavirus (HPV) Vaccine Market

19.1. Italy Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Papillomavirus (HPV) Vaccine Market

20.1. Spain Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Papillomavirus (HPV) Vaccine Market

21.1. Eastern Europe Human Papillomavirus (HPV) Vaccine Market Overview
21.2. Eastern Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Papillomavirus (HPV) Vaccine Market

22.1. Russia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Papillomavirus (HPV) Vaccine Market

23.1. North America Human Papillomavirus (HPV) Vaccine Market Overview
23.2. North America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Papillomavirus (HPV) Vaccine Market

24.1. USA Human Papillomavirus (HPV) Vaccine Market Overview
24.2. USA Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Papillomavirus (HPV) Vaccine Market

25.1. Canada Human Papillomavirus (HPV) Vaccine Market Overview
25.2. Canada Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Papillomavirus (HPV) Vaccine Market

26.1. South America Human Papillomavirus (HPV) Vaccine Market Overview
26.2. South America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Papillomavirus (HPV) Vaccine Market

27.1. Brazil Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Papillomavirus (HPV) Vaccine Market

28.1. Middle East Human Papillomavirus (HPV) Vaccine Market Overview
28.2. Middle East Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Papillomavirus (HPV) Vaccine Market

29.1. Africa Human Papillomavirus (HPV) Vaccine Market Overview
29.2. Africa Human Papillomavirus (HPV) Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Papillomavirus (HPV) Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Papillomavirus (HPV) Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Papillomavirus (HPV) Vaccine Market Competitive Landscape And Company Profiles

30.1. Human Papillomavirus (HPV) Vaccine Market Competitive Landscape
30.2. Human Papillomavirus (HPV) Vaccine Market Company Profiles
- 30.2.1. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis

31. Human Papillomavirus (HPV) Vaccine Market Other Major And Innovative Companies

31.1. AstraZeneca Pharma Ltd.
31.2. Astellas Pharma Inc.
31.3. CSL Limited
31.4. UCB SA
31.5. Serum Institute of India Pvt Ltd.
31.6. Beijing Wantai Biological Pharmacy Enterprise Co Ltd.
31.7. Emergent BioSolutions Inc.
31.8. Bharat Biotech International Ltd.
31.9. Walvax Biotechnology Co Ltd.
31.10. Bavarian Nordic AS
31.11. Biofarma Co
31.12. Vaccitech Plc
31.13. Inovio Pharmaceuticals Inc.
31.14. R-Pharm LLC
31.15. PathoVax LLC

32. Global Human Papillomavirus (HPV) Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Papillomavirus (HPV) Vaccine Market

34. Recent Developments In The Human Papillomavirus (HPV) Vaccine Market

35. Human Papillomavirus (HPV) Vaccine Market High Potential Countries, Segments and Strategies

35.1 Human Papillomavirus (HPV) Vaccine Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Papillomavirus (HPV) Vaccine Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Papillomavirus (HPV) Vaccine Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer